182 related articles for article (PubMed ID: 17260013)
1. SPARC enhances tumor stroma formation and prevents fibroblast activation.
Chlenski A; Guerrero LJ; Yang Q; Tian Y; Peddinti R; Salwen HR; Cohn SL
Oncogene; 2007 Jul; 26(31):4513-22. PubMed ID: 17260013
[TBL] [Abstract][Full Text] [Related]
2. An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium.
Gotoh N; Perdue NR; Matsushima H; Sage EH; Yan Q; Clark JI
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4679-87. PubMed ID: 17898292
[TBL] [Abstract][Full Text] [Related]
3. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells.
Hasselaar P; Sage EH
J Cell Biochem; 1992 Jul; 49(3):272-83. PubMed ID: 1644864
[TBL] [Abstract][Full Text] [Related]
4. A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.
Wu MP; Young MJ; Tzeng CC; Tzeng CR; Huang KF; Wu LW; Chou CY
Carcinogenesis; 2008 Jun; 29(6):1115-23. PubMed ID: 18413367
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.
Chlenski A; Liu S; Baker LJ; Yang Q; Tian Y; Salwen HR; Cohn SL
Cancer Res; 2004 Oct; 64(20):7420-5. PubMed ID: 15492265
[TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts.
Zhou X; Tan FK; Guo X; Wallis D; Milewicz DM; Xue S; Arnett FC
Arthritis Rheum; 2005 Jan; 52(1):257-61. PubMed ID: 15641096
[TBL] [Abstract][Full Text] [Related]
7. Type I collagen-deficient Mov-13 mice do not retain SPARC in the extracellular matrix: implications for fibroblast function.
Iruela-Arispe ML; Vernon RB; Wu H; Jaenisch R; Sage EH
Dev Dyn; 1996 Oct; 207(2):171-83. PubMed ID: 8906420
[TBL] [Abstract][Full Text] [Related]
8. Enhanced angiogenesis characteristic of SPARC-null mice disappears with age.
Reed MJ; Bradshaw AD; Shaw M; Sadoun E; Han N; Ferara N; Funk S; Puolakkainen P; Sage EH
J Cell Physiol; 2005 Sep; 204(3):800-7. PubMed ID: 15795937
[TBL] [Abstract][Full Text] [Related]
9. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.
Chlenski A; Liu S; Crawford SE; Volpert OV; DeVries GH; Evangelista A; Yang Q; Salwen HR; Farrer R; Bray J; Cohn SL
Cancer Res; 2002 Dec; 62(24):7357-63. PubMed ID: 12499280
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
11. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence.
Sage EH; Bassuk JA; Yost JC; Folkman MJ; Lane TF
J Cell Biochem; 1995 Jan; 57(1):127-40. PubMed ID: 7721952
[TBL] [Abstract][Full Text] [Related]
13. Reduced excision repair cross-complementing 1 expression associates with enhanced papilloma formation and fibroblast transformation after genetic disruption of secreted protein acidic and rich in cysteine.
Kato Y; Tsukuda M; Nagashima Y; Koshika S; Sakai N; Yao M; Kubota Y; Aoki I; Colledge WH; Foidart JM; Hata R; Thompson EW
Int J Oncol; 2005 Sep; 27(3):759-68. PubMed ID: 16077926
[TBL] [Abstract][Full Text] [Related]
14. A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire.
Clark CJ; Sage EH
J Cell Biochem; 2008 Jun; 104(3):721-32. PubMed ID: 18253934
[TBL] [Abstract][Full Text] [Related]
15. Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer.
Sugimoto T; Takiguchi Y; Kurosu K; Kasahara Y; Tanabe N; Tatsumi K; Hiroshima K; Minamihisamatsu M; Miyamoto T; Kuriyama T
Oncol Rep; 2005 Oct; 14(4):823-30. PubMed ID: 16142338
[TBL] [Abstract][Full Text] [Related]
16. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis.
Sangaletti S; Di Carlo E; Gariboldi S; Miotti S; Cappetti B; Parenza M; Rumio C; Brekken RA; Chiodoni C; Colombo MP
Cancer Res; 2008 Nov; 68(21):9050-9. PubMed ID: 18974151
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of growth factors and cytokines on the synthesis of SPARC, DNA, fibronectin and alkaline phosphatase activity in human periodontal ligament cells.
Fujita T; Shiba H; Van Dyke TE; Kurihara H
Cell Biol Int; 2004; 28(4):281-6. PubMed ID: 15109984
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
19. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
20. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix.
Chlenski A; Liu S; Guerrero LJ; Yang Q; Tian Y; Salwen HR; Zage P; Cohn SL
Int J Cancer; 2006 Jan; 118(2):310-6. PubMed ID: 16052522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
